Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study
Haemophilia · 2025-11 · 31 (6) · 1292-1297
DOI: 10.1111/hae.70141 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Haemophilia, online erschienen am 10.10.2025. Verfasst von Luigi Piero Solimeno und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Orthopaedic Surgery and Traumatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Hemophilia A, Hemophilia B, Recombinant Fusion Proteins, Factor IX. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sobi, Italian Ministry of Health-Bando Ricerca Corrente, Italian Ministry of Education and Research-MUR ('Dipartimenti di Eccellenza' Programme 2023-27-Department of Pathophysiology and Transplantation, Università de….
Abstract (Originalsprache)
Introduction
Haemophilia A and B are hereditary bleeding disorders that require multidisciplinary perioperative management. Data on orthopaedic surgery outcomes with extended‐half‐life (EHL) recombinant Fc‐fusion factor VIII (rFVIIIFc) and factor IX (rFIXFc) products remain limited.
Aims
To evaluate the efficacy of EHL rFVIIIFc or rFIXFc in major orthopaedic surgery, focusing on haemostasis, safety and factor consumption.
Methods
This prospective study involved persons with haemophilia A or B treated with rFVIIIFc or rFIXFc undergoing orthopaedic surgery.
Results
Twenty major orthopaedic surgeries (2018–2023) were included in 19 persons with severe or moderate haemophilia A ( n = 14) or B ( n = 5), median age 46 years (range 26–60). Procedures included arthroplasty, arthrodesis, arthroscopic synovectomy, prosthetic revision of the knee or ankle, and removal of a femur fracture fixation device. Median hospital stay was 7 days (range 2–18). Median cumulative factor consumption was 300 and 388 IU/kg for haemophilia A and B, respectively. Haemostatic efficacy was rated as ‘good’ in 95% ( n = 18) of cases, ‘poor’ in 5% ( n = 1), and not documented in one case. Median haemoglobin (Hb) change was –2.0 g/dL (range –4.6 to +0.5); no transfusions were required. Complications were reported in 45% ( n = 9) of cases (anaemia 40%; blood loss 5%) and managed with oral supplementation of iron and folates. No adverse events related to rFVIIIFc or rFIXFc administration were observed.
Conclusion
RFVIIIFc and rFIXFc provide effective haemostasis during orthopaedic surgery in patients with haemophilia A and B, with a favourable safety profile. Further multicentre studies are warranted to confirm these results and refine perioperative management guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Orthopaedic Surgery and Traumatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
- Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy.
- Orthopaedic Clinic, University of Florence, Firenze, Italy.
- Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy.
ORCID-Profile: Luigi Piero Solimeno, Roberta Gualtierotti, Emanuele Guido, Jacopo Acquati Lozej, Alessandro Ciavarella, Sara Arcudi, Christian Carulli, Lisa Pieri, Simona Maria Siboni, Flora Peyvandi
Förderung
- Sobi
- Italian Ministry of Health-Bando Ricerca Corrente
- Italian Ministry of Education and Research-MUR ('Dipartimenti di Eccellenza' Programme 2023-27-Department of Pathophysiology and Transplantation, Università de…
- Swedish Orphan Biovitrum
Zitieren
APA
Solimeno, L. P., Gualtierotti, R., Guido, E., Acquati Lozej, J., Cristini, E., Ciavarella, A., Arcudi, S., Carulli, C., Pieri, L., Siboni, S. M., & Peyvandi, F. (2025). Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study. Haemophilia, 31(6), 1292-1297. https://doi.org/10.1111/hae.70141
Vancouver
Solimeno LP, Gualtierotti R, Guido E, Acquati Lozej J, Cristini E, Ciavarella A, et al. Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study. Haemophilia. 2025;31(6):1292-1297. doi:10.1111/hae.70141
BibTeX
@article{Solimeno2025,
author = {Solimeno, Luigi Piero and Gualtierotti, Roberta and Guido, Emanuele and Acquati Lozej, Jacopo and Cristini, Enrica and Ciavarella, Alessandro and Arcudi, Sara and Carulli, Christian and Pieri, Lisa and Siboni, Simona Maria and Peyvandi, Flora},
title = {Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study},
journal = {Haemophilia},
year = {2025},
volume = {31},
number = {6},
pages = {1292--1297},
doi = {10.1111/hae.70141}
}
EUVIMED